QUICK ANSWER
P-tau217 (phosphorylated tau at threonine 217) is a blood plasma biomarker that reflects Alzheimer's disease-related brain changes — specifically the presence of amyloid plaques and tau pathology — before or alongside symptoms.
Reference ranges vary by assay and lab. The most widely used clinical platform is Lumipulse (Fujirebio), for which Mayo Clinic and published validation studies use these approximate thresholds:
| Result | Lumipulse p-tau217 (pg/mL) | Interpretation |
|---|---|---|
| Negative | ≤ 0.18–0.20 | AD-type pathology unlikely at this time |
| Indeterminate / Gray zone | 0.18–0.32 | Borderline — confirmatory testing or repeat may be needed |
| Positive | ≥ 0.32–0.33 | AD-type amyloid/tau pathology likely |
Always use the reference range and cutoffs printed on your own lab report. Different assay platforms (Lumipulse, ALZpath, C2N AD-Detect, mass spectrometry-based) use different cutoff values that are not interchangeable.
If you have a specific Lumipulse result — what it typically means:
| Example result (pg/mL) | Typical interpretation on Lumipulse |
|---|---|
| 0.10–0.12 | Clearly negative — AD-type pathology unlikely |
| 0.18 | Near the negative threshold — typically negative |
| 0.22–0.25 | Indeterminate / gray zone — further evaluation often recommended |
| 0.30–0.32 | Near the positive threshold — borderline; clinician judgment required |
| 0.40+ | Clearly positive — AD-type pathology likely |
These values apply to the Lumipulse platform only and cannot be compared to results from AD-Detect, ALZpath, or other assays.
Key takeaway: A positive p-tau217 result increases the likelihood of Alzheimer's-type pathology — it does not confirm an Alzheimer's disease diagnosis. Interpretation requires the clinical picture, cognitive testing, and often confirmatory testing.
WHAT IS P-TAU217?
Tau is a protein that stabilizes structures inside neurons. In Alzheimer's disease, tau becomes abnormally phosphorylated at specific sites — including threonine 217 — and forms toxic tangles inside brain cells. Phosphorylated tau-217 (p-tau217) leaks into the bloodstream as this process occurs, making it detectable by a blood test.
Why p-tau217 specifically?
- P-tau217 rises earlier and more steeply in Alzheimer's disease than other phospho-tau variants (p-tau181, p-tau231)
- It reflects both amyloid plaque formation and tau tangle pathology simultaneously
- Its plasma levels correlate strongly with amyloid PET and CSF biomarker results
- In head-to-head comparisons, p-tau217 generally shows higher diagnostic accuracy than p-tau181 for identifying AD-type pathology
FDA clearance: The Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio assay received FDA 510(k) clearance on May 16, 2025 — the first FDA-cleared blood-based diagnostic test to aid in identifying amyloid pathology associated with Alzheimer's disease. Labcorp launched nationwide availability of the test in August 2025. This marked a major shift from primarily research and specialty-center use toward broad clinical availability in the US.
WHAT DOES A HIGH P-TAU217 MEAN?
A high p-tau217 (above the positive cutoff for your assay) means Alzheimer's-type amyloid and tau pathology is likely present in the brain. The higher the value above the positive threshold, the stronger the signal.
What this means clinically:
- The brain changes associated with Alzheimer's disease are likely occurring
- It supports — but does not confirm — a clinical diagnosis of Alzheimer's disease
- Your clinician may recommend confirmatory testing (amyloid PET scan or CSF biomarkers) if the result would change management
- It may support eligibility for Alzheimer's disease-modifying treatments (lecanemab, donanemab) which require confirmed amyloid pathology
What a high result does not mean:
- It does not mean you will definitely develop Alzheimer's dementia
- It does not measure the rate of progression
- It is not a standalone diagnosis — clinical symptoms and cognitive testing are always required
WHAT DOES A LOW P-TAU217 MEAN?
A low p-tau217 (below the negative cutoff for your assay) makes Alzheimer's-type amyloid and tau pathology unlikely at this time. It is a reassuring result in a patient being evaluated for possible Alzheimer's disease.
What this means clinically:
- AD-type pathology is less likely as the explanation for current cognitive symptoms
- It may redirect evaluation toward other causes of cognitive change (vascular dementia, Lewy body dementia, depression, metabolic causes)
- It does not completely exclude early or preclinical Alzheimer's disease
A negative result, like all biomarker tests, is most meaningful when combined with clinical assessment and cognitive testing.
WHAT DOES AN INDETERMINATE / GRAY ZONE RESULT MEAN?
Many labs report p-tau217 using a two-cutoff approach — a lower negative threshold and a higher positive threshold — with a gray zone in between. This is intentional.
Why two cutoffs? The two-cutoff strategy improves overall diagnostic accuracy by reserving the highest-confidence "positive" and "negative" calls for results clearly outside the ambiguous middle range. Studies show that roughly 70–85% of patients can be classified with high confidence (negative or positive) using this approach, while 15–30% fall in the intermediate zone.
What to do with an indeterminate result:
- Your clinician will weigh the result alongside cognitive testing, symptoms, and other biomarkers (Aβ42, p-tau217/Aβ42 ratio, NfL)
- Repeat testing after 6–12 months may be recommended if symptoms progress
- Amyloid PET or CSF biomarkers may be ordered for definitive classification
- An indeterminate result is not a "bad" result — it reflects honest uncertainty rather than failure of the test
WHY DO REFERENCE RANGES DIFFER BY ASSAY?
The same patient's blood measured on different p-tau217 platforms will produce different absolute numbers. This is because each assay uses different antibodies, detection methods, and calibrators.
The major commercial platforms and their characteristics:
| Platform | Manufacturer | Method | Common clinical use |
|---|---|---|---|
| Lumipulse | Fujirebio | Chemiluminescent immunoassay (CLEIA) | FDA-cleared; widely used in US hospital labs |
| ALZpath Simoa | ALZpath | Single molecule array (Simoa) | High sensitivity; used in research and specialty clinics |
| AD-Detect | C2N Diagnostics | Mass spectrometry (%p-tau217) | Reports as percentage, not absolute pg/mL |
| PrecivityAD2 | C2N Diagnostics | Mass spectrometry + algorithm | Combines %p-tau217 with Aβ42/40 ratio |
This is why the ranges differ: An "indeterminate" result on Lumipulse may correspond to a different absolute number than an "indeterminate" on ALZpath. Do not attempt to apply one platform's cutoffs to another platform's results.
P-TAU217 AND THE P-TAU217/Aβ42 RATIO
Some labs report the p-tau217/Aβ42 ratio alongside or instead of p-tau217 alone. Adding Aβ42 improves discrimination because:
- Aβ42 falls as amyloid plaques accumulate (it gets "trapped" in the brain)
- P-tau217 rises as pathology advances
- The ratio therefore moves in a direction more powerfully than either marker alone
The Lumipulse FDA-cleared assay specifically measures the p-tau217/Aβ42 ratio. A high ratio (elevated p-tau217 combined with low Aβ42) strengthens the indication of AD pathology beyond p-tau217 alone.
CAN P-TAU217 BE ELEVATED BEFORE SYMPTOMS APPEAR?
Yes. P-tau217 can become abnormal years — potentially a decade or more — before dementia develops. This is one of the most clinically important features of the biomarker.
Alzheimer's disease pathology (amyloid plaques and tau tangles) begins accumulating in the brain well before memory loss or cognitive symptoms become apparent. P-tau217 reflects this underlying biological process, not the severity of current memory loss. This means:
- A person with elevated p-tau217 may currently have mild cognitive impairment (MCI), subjective memory concerns, or even no obvious symptoms at the time of testing
- An elevated result in a person without symptoms does not mean dementia is imminent — it indicates the biological process is underway
- Early detection is the point: identifying Alzheimer's-type pathology before significant neuronal loss has occurred is precisely when disease-modifying treatments may have the greatest potential benefit
What presymptomatic elevation does not mean:
- It does not predict with certainty that dementia will develop — not all people with amyloid pathology progress to symptomatic disease
- It does not indicate how quickly symptoms will appear
- It does not mean that immediate treatment is required in all cases — decisions about intervention depend on the full clinical picture
WHEN IS THE P-TAU217 TEST ORDERED?
P-tau217 is typically ordered in adults with:
- New or progressive memory and thinking changes under evaluation for possible Alzheimer's disease
- Mild cognitive impairment (MCI) where clarifying the underlying cause would change management
- Atypical presentations where Alzheimer's vs. another dementia is unclear
- Pre-treatment workup for patients being considered for amyloid-targeting therapies (lecanemab, donanemab)
- Situations where amyloid PET or lumbar puncture is not accessible, not desired, or has already been deferred
The test is not currently recommended as routine screening in cognitively normal individuals without symptoms. Its performance in the general asymptomatic population is less well established.
WHEN TO FOLLOW UP
Discuss your p-tau217 result with a clinician if:
- Your result is in the positive range — confirmatory amyloid PET or CSF testing may be recommended
- Your result is indeterminate — repeat testing or additional biomarkers may be ordered
- Your result is negative but symptoms are progressing — other causes of cognitive change need evaluation
- You are considering or already on Alzheimer's disease-modifying therapy
BOTTOM LINE
Bottom line: P-tau217 is a blood plasma biomarker that identifies Alzheimer's-related brain changes. A positive result (above the assay-specific cutoff) increases the likelihood of AD pathology; a negative result makes it less likely. Cutoffs differ significantly between platforms — Lumipulse, ALZpath, AD-Detect, and PrecivityAD2 are not interchangeable. An indeterminate (gray zone) result is common and prompts further evaluation rather than a definitive conclusion. P-tau217 is an aid to diagnosis, not a diagnosis itself.
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →Frequently Asked Questions
Can p-tau217 go back to normal?
What is a normal p-tau217 range?
What does a high p-tau217 mean?
What does it mean if my p-tau217 is in the gray zone?
Is the p-tau217 test the same as an Alzheimer's diagnosis?
What is the difference between p-tau217 and p-tau181?
Do I still need a PET scan or lumbar puncture after a p-tau217 result?
Why does my number look different from ranges I find online?
What if my p-tau217 is intermediate but my amyloid PET scan is positive?
Can kidney disease affect p-tau217 results?
All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.
-
Plasma p-tau217 in Alzheimer's disease: Lumipulse and ALZpath SIMOA head-to-head comparison
-
Clinical performance of the fully automated Lumipulse plasma p‐tau217 assay in mild cognitive impairment and mild dementia
-
Plasma phospho-tau217 for Alzheimer's disease diagnosis in primary and secondary care using a fully automated platform
-
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis